Manufacturing · Profile from Manufacturing Research Companion: Companies, Strategic Moves, and Technical Studies

3D Systems

The company that invented the 3D-printing industry — Chuck Hull's stereolithography patent (filed 1984, granted 1986) and the business he founded to sell it (from memory, verify dates) — and that spent the next forty years looking for a product worth making at scale. 3D Systems' manufacturing story turns on an inventor's head start that never became a production business: rapid-prototyping machines for design offices in the 1990s and 2000s; a roll-up of roughly 40 companies and a consumer push (the Cube printer and the Cubify brand) in the 2011–15 hype cycle, followed by write-downs; a 2020 restructuring that sold non-core units; a failed attempt in 2023 to buy Stratasys and stop its merger with Desktop Metal; and a 2025 sale of software businesses (Geomagic to Hexagon for ~$119.4m of cash; Oqton and 3DXpert to Hubb Global Holdings for $3.3m plus a royalty) to fund a smaller company focused on dental, healthcare and industrial polymer and metal printing. FY2025 revenue was $386.9m (−12%); Q3 2026 revenue $99.3m (+8.8%) with a GAAP net loss of $33.5m (10-K, 8-K). The parts that work — dental aligner materials, medical devices printed to order, aerospace and semiconductor-equipment parts — are low-volume, high-value niches, and the printer business around them has never earned a steady profit.

At a glance

Founded: 1986, Valencia, California, by Charles (Chuck) Hull to commercialise stereolithography (from memory, verify); first commercial SLA machine sold ~1987–88 (from memory, verify)
Headquarters: Rock Hill, South Carolina (moved from California in the mid-2000s — from memory, verify)
Ownership / structure: Public (NYSE: DDD)
Leadership (2026): Jeff Graves, president and CEO (from 2020 — from memory, verify); Chuck Hull, co-founder and long-time chief technology officer (status in 2026 verify)
Segments: Healthcare Solutions (dental, medical devices and printed implants, regenerative medicine) and Industrial Solutions (aerospace and defence, semiconductor equipment, automotive, general industry; printers, materials, software and on-demand parts)
Scale: FY2025: revenue $386.9m (−12%; ~−7% excluding Geomagic), Healthcare $179.6m, Industrial $207.3m; net income attributable $29.9m (vs a $255.6m loss in 2024), driven by divestiture gains (10-K / Q4 release). Q3 2026: revenue $99.3m (+8.8%; +10.9% excluding the 2025 software divestitures), Healthcare $49.0m (+14.4%), Industrial $50.3m (+3.9%), gross margin 35.0% (32.3%), adjusted EBITDA $3.1m, GAAP net loss attributable $33.5m (8-K, 10-Q)
Plants (US, selected): Rock Hill, South Carolina (HQ, materials); Littleton, Colorado (healthcare and printed medical devices — from memory, verify); Wilsonville, Oregon and other US sites (verify current list); Leuven, Belgium (healthcare and software — from memory, verify)
Signature moves (incl. failures): Stereolithography patent and founding (1986); the acquisition spree (~40 deals, 2009–15); the Cube and Cubify consumer push (2012–15); write-downs and Reichental's exit (2015); the 2020 restructuring and divestments; Systemic Bio and regenerative medicine (2022–); the Stratasys bids (2023, failure); the 2025 software divestitures and cost reset

8 strategic moves analysed

Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.

1986
Stereolithography Patent and Founding
Founding / technology bet (a new manufacturing process and the company to commercialise it)
2011
Acquisition Spree and Z Corporation
Acquisition (serial roll-up of printer, materials, software, scanning, service-bureau and consumer companies)
2013
Cube Cubify and the Consumer Hype
Product launch and strategy pivot (consumer 3D printers, a consumer brand and online content) — later abandoned (failure)
2015
Write Downs and the Consumer Retreat
Write-down and restructuring (failure of the roll-up and consumer strategy); leadership change
2020
Restructuring and Divestments
Restructuring and divestment (portfolio narrowing into Healthcare and Industrial segments, sale of non-core software and services, cost cuts)
2022
Systemic Bio and Regenerative Medicine
Technology bet (bioprinting for drug discovery and regenerative medicine), organised partly as a separately branded venture
2023
Stratasys Bids and the Consolidation Contest
Acquisition attempt (unsolicited offers for Stratasys, designed also to stop the Stratasys–Desktop Metal merger) — failure
2025
Software Divestitures and Cost Reset
Divestment and restructuring (sale of Geomagic to Hexagon; sale of Oqton and 3DXpert to Hubb Global Holdings; spending cuts)